Evidence map›Paper›PMID 40780460›Full record

ArticleBioorganic & medicinal chemistry letters2025

Synthesis and antibacterial activity of novel benzodioxin-containing oxazolidinones against M. abscessus.

Connor M Winkelhake, Binayak Rimal, Ben A Thomas, Joe B Huisken, Gyanu Lamichhane, J Thomas Ippoliti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Connor M WinkelhakeDepartment of Chemistry, University of St. Thomas, 2115 Summit Ave, St. Paul, MN 55105, United States.
Binayak RimalTaskforce for Resistance Emergence & Antimicrobial Technology and Center for Non-tuberculous Mycobacteria and Bronchiectasis, Department of Medicine, Johns Hopkins University, 1550 Orleans St, Baltimore, MD 21287, United States.
Ben A ThomasDepartment of Chemistry, University of St. Thomas, 2115 Summit Ave, St. Paul, MN 55105, United States.
Joe B HuiskenDepartment of Chemistry, University of St. Thomas, 2115 Summit Ave, St. Paul, MN 55105, United States.
Gyanu LamichhaneTaskforce for Resistance Emergence & Antimicrobial Technology and Center for Non-tuberculous Mycobacteria and Bronchiectasis, Department of Medicine, Johns Hopkins University, 1550 Orleans St, Baltimore, MD 21287, United States. Electronic address: lamichhane@jhu.edu.
J Thomas IppolitiDepartment of Chemistry, University of St. Thomas, 2115 Summit Ave, St. Paul, MN 55105, United States. Electronic address: jtippoliti@stthomas.edu.

Funding

A strategy for new regimens to treat pulmonary Mycobacteroides abscessus infectionR01AI155664 · NIAID · JOHNS HOPKINS UNIVERSITY · PI LAMICHHANE, GYANU · 2020 to 2024
$2.1M
NIAID NIH HHS R01 AI155664
6 · The paper itself

Abstract

Mycobacterium abscessus infections represent a significant treatment challenge, owing to the lack of effective therapies, and the intensive multidrug regimens currently recommended for this indication. Oxazolidinone antibiotics such as linezolid have been used to treat this complex disease. Utilizing a strategic structural extension strategy, five novel oxazolidinone derivatives were synthesized by the introduction of oxime, nitrile, amide, amidoxime, and oxime ester functional groups to a previously reported benzodioxin-scaffold. The in vitro activities of these derivatives against M. abscessus were assessed, with the amidoxime derivative exhibiting activity superior to linezolid.

Indexed as

Anti-Bacterial AgentsMycobacterium abscessusOxazolidinonesMicrobial Sensitivity TestsMolecular StructureStructure-Activity RelationshipAnti-Bacterial AgentsOxazolidinonesAntibacterial activitiesAntibioticsMycobacterium abscessusMycobacteroides abscessusOxazolidinonesSynthesis

Identifiers

PMID40780460
PMCPMC12401167

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.